AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate wins two new indications based on pivotal DESTINY-Breast11 and DESTINY-Breast05 trials, reshaping …
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate wins two new indications based on pivotal DESTINY-Breast11 and DESTINY-Breast05 trials, reshaping …
The FDA approval of Xocova marks a new front in the antiviral arsenal, shifting from treatment to prevention …
The stealth-mode startup emerges with a pipeline targeting focal epilepsy, schizophrenia, tinnitus, and reversible encephalopathy — all acquired …
BioMarin Pharmaceutical has announced positive pivotal Phase 3 results for VOXZOGO (vosoritide) in children with hypochondroplasia, the most …
The U.S. Food and Drug Administration has approved VEPPANU (vepdegestrant), marking a significant milestone as the first PROTAC …
The global Alzheimer’s disease drug development pipeline has reached an unprecedented scale in 2026, with 192 active clinical …
Global biopharmaceutical mergers and acquisitions have surged to $106 billion across 201 transactions in 2026, putting the sector …
A phase 1 pilot trial suggests that a novel egg-shell derived peptide may reduce Alzheimer’s biomarkers and improve …
One company faces regulatory setback while another achieves a Phase III victory, highlighting both urgency and uncertainty in …
Regulatory setback for one biotech contrasts with a major success in sleep disorder treatment, underscoring the high stakes …